Business Context and Reporting Period
Company: NeoGenomics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2026
Reporting Period: Immediate event reported on June 23, 2026, with a press release issued on June 25, 2026.
Key Financial Metrics
This filing does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten directors.
- Director Appointment: Carolyn S. Starrett was appointed as a director to fill the newly created vacancy, effective immediately.
- Term: Ms. Starrett will serve until the 2027 annual meeting of stockholders or until her successor is elected and qualified.
- Compensation: Ms. Starrett will receive compensation consistent with the Company's existing director compensation program.
Guidance, Outlook, and Risks
This filing does not provide updated financial guidance, outlook, management commentary on operations, or new risk factors. The document focuses solely on the corporate governance change regarding the Board of Directors.
Investor Verification Checklist
- Verify the qualifications and background of the newly appointed director, Carolyn S. Starrett.
- Review the definitive proxy statement for the 2026 annual meeting to confirm the specific compensation structure for independent directors.
- Confirm the effective date of the Board size increase and the term end date for the new director.